Adagio Medical Holdings Inc. (ADGM)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Adagio Medical Holdings, Inc. (NASDAQ:ADGM) Sees Large Growth in Short Interest
Adagio Medical Holdings, Inc. (NASDAQ: ADGM - Get Free Report) was the recipient of a large increase in short interest in April. As of April 15th, there was short interest totaling 50,386 shares, an increase of 106.5% from the March 31st total of 24,396 shares. Based on an average trading volume of 299,319 shares, the short-interest
Adagio Medical Holdings Inc. (ADGM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Adagio Medical Holdings Inc. ever had a stock split?
Adagio Medical Holdings Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Todd Usen CEO | NASDAQ (CM) Exchange | 00534B100 CUSIP |
| US Country | 80 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Adagio Medical Holdings, Inc. is a developmental stage medical device company specializing in the innovation of ablation technologies aimed at treating cardiac arrhythmias. The company's primary focus is on offering advanced treatment solutions for various types of cardiac arrhythmias, such as atrial fibrillation, atrial flutter, and ventricular tachycardia. Founded in 2011 and based in Laguna Hills, California, Adagio is at the forefront of developing groundbreaking medical devices to address the needs of patients suffering from these heart conditions.
Products and Services
- iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories
This product represents Adagio Medical Holdings, Inc.'s pioneering approach to the treatment of atrial fibrillation and atrial flutter. The iCLAS system utilizes ultra-low temperature cryoablation technology, designed to safely freeze and ablate faulty electrical pathways in the heart, thereby restoring normal heart rhythm.
- vCLAS ventricular ULTC catheter
The vCLAS ventricular ULTC catheter targets ventricular tachycardia, a condition characterized by a fast heart rhythm originating from the heart's lower chambers. By applying the same ultra-low temperature cryoablation technology as its atrial counterpart, the vCLAS catheter aims to treat this dangerous arrhythmia by ablating the areas responsible for the erratic heartbeats.
- Cryopulse atrial pulsed-field cryoablation catheter and accessories
Expanding its portfolio, Adagio introduces the Cryopulse atrial pulsed-field cryoablation catheter, a novel device that combines the benefits of cryoablation with pulsed-field ablation. This combination aims to offer a more targeted and efficient treatment for atrial fibrillation, potentially improving outcomes and reducing procedural times.
